Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Nexium TV Ad Claims Superiority To TAP's Prevacid

This article was originally published in The Pink Sheet Daily

Executive Summary

The ad claims Nexium heals esophageal damage better than "the other leading prescription medicine." AstraZeneca says it has conducted two head-to-head studies that should satisfy FDA's requirement for "substantial evidence or substantial clinical experience" in making comparative claims.

You may also be interested in...



Nexium Branded Campaign Will Highlight Use With NSAIDs

AstraZeneca says the ads will debut "within the coming weeks." The spots will conform to the company's new principles that highlight "direct" presentation of risk/benefit information and the benefits of early detection.

Nexium Branded Campaign Will Highlight Use With NSAIDs

AstraZeneca says the ads will debut "within the coming weeks." The spots will conform to the company's new principles that highlight "direct" presentation of risk/benefit information and the benefits of early detection.

DTC Ad Comparative Claims Draw FDA Criticism, Even With “Scientific Basis”

“We’re not pleased with the way direct-to-consumer advertising is going,” Acting Commissioner Crawford says. DTC ads have become “ridiculous,” he says; “very strong measures” by FDA may be warranted.

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel